4//SEC Filing
Neervannan Seshadri 4
Accession 0001819790-25-000043
CIK 0001819790other
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 9:39 PM ET
Size
11.7 KB
Accession
0001819790-25-000043
Insider Transaction Report
Form 4
Neervannan Seshadri
Chief Operating Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-15+21,264→ 87,265 total - Exercise/Conversion
Restricted Stock Units
2025-03-15−8,019→ 24,060 total→ Common Stock (8,019 underlying) - Exercise/Conversion
Restricted Stock Units
2025-03-15−5,097→ 5,097 total→ Common Stock (5,097 underlying) - Exercise/Conversion
Restricted Stock Units
2025-03-15−8,148→ 16,296 total→ Common Stock (8,148 underlying)
Footnotes (6)
- [F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
- [F2]Includes 1,234 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2024.
- [F3]Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- [F4]RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service.
- [F5]RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
- [F6]RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.
Documents
Issuer
Tarsus Pharmaceuticals, Inc.
CIK 0001819790
Entity typeother
Related Parties
1- filerCIK 0001827584
Filing Metadata
- Form type
- 4
- Filed
- Mar 17, 8:00 PM ET
- Accepted
- Mar 18, 9:39 PM ET
- Size
- 11.7 KB